Health

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University of Toronto-linked Deep Genomics has picked up $180m in its series C round led by SoftBank Vision Fund 2.

Rakuten and SBI have returned to chip into the precision immunotherapy developer’s series D round, which was led by General Catalyst.

SoftBank and Alexandria Real Estate Equities helped the Bloomberg-backed genetic medicine developer raise series C funding to further expand its pipeline of RNA therapies.

MicroPort's implantable implantable defibrillator and pacemaker spinoff has secured funding in a series C round co-led by its parent company.

Carbon-neutral blockchain technology developer Core Scientific raised $54m from Celsius while autoimmune disease therapy developer Topas Therapeutics took a BIVF-backed round past $47m.

Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.

Based on research originally conducted at MIT, Tepha has been purchased by BD for an undisclosed sum.

UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.

Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Cornell-linked dog DNA test developer Embark Veterinary raised the capital in a round led by SoftBank Vision Fund 2 at a $700m post-money valuation.